Table 1. Demographics (n=61).
| Total number of patients | Value |
|---|---|
| Age (years) | 66 [48–83] |
| Gender | |
| Female | 23 [38] |
| Male | 38 [62] |
| Ethnicity | |
| White | 53 [87] |
| Others | 8 [13] |
| Primary tumor location | |
| Head | 46 [75.4] |
| Body/tail | 15 [24.6] |
| Sites of metastasis | |
| Liver | 41 [67] |
| LN | 20 [33] |
| Lung | 22 [36] |
| Bone | 5 [8] |
| CA19-9 at SBRT | |
| <200 U/mL | 43 [70.5] |
| ≥200 U/mL | 18 [29.5] |
| Chemotherapy regimen | |
| 5-FU-based | 21 [34.4] |
| Gemcitabine-based | 23 [37.7] |
| Others | 17 [27.9] |
| Radiation dose (Gy) | 50 [20–60] |
| No. of fractions | 5 [1–15] |
Data are expressed as median [range] or n [%]. 5-FU, 5-fluorouracil; LN, lymph node; SBRT, stereotactic body radiation therapy.